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Abstract
Background—Preoperative breast magnetic resonance imaging (MRI) use among Medicare 
beneficiaries with breast cancer has substantially increased from 2005 to 2009. We sought to 
identify factors associated with preoperative breast MRI use among women diagnosed with ductal 
carcinoma in situ (DCIS) or stage I-III invasive breast cancer (IBC).
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Methods—Using Surveillance, Epidemiology, and End Results and Medicare data from 2005 to 
2009 we identified women ages 66 and older with DCIS or stage I-III IBC who underwent breast 
conserving surgery or mastectomy. We compared preoperative breast MRI use by patient, tumor 
and hospital characteristics stratified by DCIS and IBC using multivariable logistic regression.
Results—From 2005 to 2009, preoperative breast MRI use increased from 5.9% to 22.4% of 
women diagnosed with DCIS and 7.0% to 24.3% of women diagnosed with IBC. Preoperative 
breast MRI use was more common among women who were younger, married, lived in higher 
median income zip codes and had no comorbidities. Among women with IBC, those with lobular 
disease, smaller tumors (< 1 cm) and those with estrogen receptor negative tumors were more 
likely to receive preoperative breast MRI. Women with DCIS were more likely to receive 
preoperative MRI if tumors were larger (> 2cm).
Conclusion—The likelihood of receiving preoperative breast MRI is similar for women 
diagnosed with DCIS and IBC. Use of MRI is more common in women with IBC for tumors that 
are lobular and smaller while for DCIS MRI is used for evaluation of larger lesions.
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Introduction
For planning of surgical treatment of breast cancer, preoperative imaging with 
mammography, ultrasound or breast magnetic resonance imaging (MRI) allows for 
assessment of disease extent with the goal of improving patient outcomes such as re-
excision rates, morbidity and breast cancer mortality. Breast MRI is increasingly used for 
this purpose, although there is no consensus that MRI improves short- or long-term 
outcomes (i.e. 5 year survival) over imaging with mammography or ultrasound, or 
preferentially benefits particular groups of women based on patient or tumor factors.(1)
Multiple studies have reported that preoperative breast MRI use among women with a breast 
cancer diagnosis increased dramatically from approximately 1% in 2001 to 25-53% in 
2008/2009.(2-5) The current National Comprehensive Cancer Network (NCCN) guidelines 
state that breast MRI may be considered for women newly diagnosed with invasive breast 
cancer (IBC) in order to determine the extent of disease and to screen the contralateral 
breast, particularly for women at increased risk for mammographically occult disease.(1) In 
multiple studies of MRI in patients with newly diagnosed breast cancer, MRI has been 
shown to identify additional otherwise-occult disease, detecting additional breast cancer in 
approximately 16% of women.(6) However, studies to-date of breast MRI have not been 
associated with decreased re-excision rates, recurrence rates or improved survival.(7-9) 
Preoperative breast MRI has been shown to increase anxiety, as well as to be associated with 
more biopsies and higher mastectomy rates. Such additional procedures are for findings of 
otherwise occult disease and additional breast cancer.(10, 11)
We analyzed trends in the utilization of preoperative breast MRI from 2005-2009 as well as 
patient factors, tumor features and hospital characteristics associated with its use, separately 
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for ductal carcinoma in-situ (DCIS) and stage I-III IBC. We sought to determine whether 
tumor features, such as estrogen receptor status, associated with use of breast MRI differed 
for DCIS compared to IBC. Although several prior studies have utilized Surveillance, 
Epidemiology, and End Results (SEER)-Medicare data to explore preoperative breast MRI 
diffusion and to identify factors associated with its use (3, 5), our study extends these 
previous studies by 1) examining DCIS and IBC separately; 2) more precisely defining the 
preoperative window; and 3) examining the impact of hospital characteristics on MRI use.
Material and Methods
Data Sources
We used data from the National Cancer Institute's linked SEER-Medicare data, which 
includes 17 population based cancer registries linked to Medicare administrative and health 
care claims data.(12) The SEER-Medicare data have been used to study health disparities, 
quality of care and cost of care across the cancer control continuum.(13) All patient data 
from the SEER-Medicare data used in this study were de-identified.
Study Population
The study cohort included women with DCIS or stage I-III IBC diagnosed between 2005 
and 2009 who received BCS or mastectomy within 6 months of breast cancer diagnosis. 
Receipt of BCS and mastectomy was based on Current Procedural Terminology (CPT)/
Healthcare Common Procedure Coding System (HCPCS) and International Classification of 
Disease (ICD-9) codes in the Medicare claims. We included women age 66 or older at breast 
cancer diagnosis with a pathologically confirmed diagnosis and for whom the reporting 
source of diagnosis was not a nursing home. To ensure complete capture of claims, we 
required women to be Medicare Parts A and B enrolled and non-HMO enrolled for one-year 
prior to and six-months post breast cancer diagnosis. We excluded women with a personal 
history of breast cancer because we were interested in incident disease. We further excluded 
women with unknown race, unknown residence, unknown census tract median income and 
ER borderline status because of small cell sizes.
Outcomes
Receipt of preoperative MRI was identified from Medicare outpatient or physician claims 
based on CPT/HCPCS and ICD-9 codes. We defined the preoperative window as the time 
between breast cancer diagnosis date (defined as the biopsy date closest to the SEER 
diagnosis date or the first of the month of the SEER diagnosis date if there was no biopsy 
date (approximately 3% of women)) and breast surgery claim date (either BCS or 
mastectomy) and limited the preoperative window to a maximum of 6 months (median 
preoperative window is 24 days with interquartile range of 14 to 39 days). Using SEER-
Medicare data to define a preoperative window is not straightforward because SEER assigns 
the cancer diagnosis date as the 15th day of the month in which the cancer was diagnosed. 
To determine a more specific cancer diagnosis date and refine the preoperative window we 
identified the breast biopsy date closest to the SEER diagnosis date to anchor the beginning 
of the preoperative window. For this analysis we compared the use of preoperative MRI 
versus no preoperative MRI.
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Predictor Variables
Demographic data included age, race (black, white, and other (Asian, Hispanic, Native 
American Indian, and other)), ethnicity, marital status, geographic region based on SEER 
registry, rural/urban location based on county of residence (urban includes big metropolitan, 
metropolitan, and urban; rural includes less urban and rural; see http://
appliedresearch.cancer.gov/seermedicare/medicare/Sumden.requests.pdf for additional 
information), median income of the 2000 census tract in which the woman resided, 
diagnosis year and a measure of comorbidity based on a validated claims-based algorithm.
(14) Using the SEER behavior codes and stage variable, we classified women with DCIS or 
invasive disease (including stage I-III). Tumor characteristic data was obtained from SEER 
sources and includes histology (invasive ductal cancer (IDC), invasive lobular cancer (ILC), 
invasive lobular and ductal, and other (papillary, tubular, mucinous, medullary, 
inflammatory, metaplastic, sarcoma)), grade, AJCC stage, size, and estrogen receptor (ER) 
status. From the SEER-Medicare provider and hospital files we ascertained characteristics of 
the hospitals where the surgery was performed including teaching hospital and if the hospital 
participated in at least one National Cancer Institute (NCI)-sponsored cooperative group trial 
at the time of the breast surgery.
Statistical Analysis
We compared the unadjusted distribution of preoperative MRI use by woman and tumor 
characteristics stratified by cancer type (DCIS and invasive) using the chi-square test. A 
multivariable logistic regression model identified patient, tumor and hospital characteristics 
associated with receipt of preoperative breast MRI, for women with DCIS and those with 
invasive disease. SAS 9.3 (15) was used for all analyses and a two-sided p-value of 0.05 
defined statistical significance.
We conducted a sensitivity analysis to determine the impact that adjustment of our 
preoperative window to capture MRI conducted in the 30 days prior to the diagnosis date 
would have on the results.
Results
Of the 55,334 women with non-metastatic breast cancer who underwent BCS or 
mastectomy, 8,979 (16.2%) received preoperative MRI. From 2005 to 2009 the use of 
preoperative breast MRI increased significantly (p-value for trend <0.0001) at 
approximately the same rate for DCIS and IBC (Figure 1). Preoperative breast MRI 
utilization rose from 5.9% in 2005 to 22.4% in 2009 for women with DCIS and from 7.0% 
to 24.3% during the same time period for women with IBC. Geographic variation in use was 
evident across SEER sites with lower rates in the southeast and higher rates in the west 
(Figure 2).
Women who were younger, white, lived in urban areas, were married, lived in a zip code 
with a higher median income and had a comorbidity score of zero were more likely to 
receive MRI (Table 1). Among women with DCIS, those with low grade, larger tumors and 
those whose surgery was performed at a hospital that participated in an NCI cooperative 
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group trial were more likely to receive preoperative breast MRI. For women with invasive 
cancer, those with ILC, high to intermediate grade, smaller size, who had their surgery at a 
teaching hospital or a hospital that participated in an NCI sponsored cooperative group trial 
were more likely to receive preoperative breast MRI.
The use of preoperative breast MRI increased for all race groups from 2005 to 2008 but then 
decreased in 2009 for black and other non-white/non-black women with DCIS (Figure 3A). 
Among women with DCIS, there was no significant difference in MRI use between blacks 
and whites in 2005 and 2006 but from 2007 to 2009, MRI use was consistently higher 
among white than black women. For women with invasive cancer, preoperative MRI use 
was consistently higher for white compared with black women. The proportion of women 
receiving preoperative breast MRI was higher for those with ILC from 2005 to 2009 (Figure 
3B). With regard to tumor size, there was a sharp increase in use of preoperative MRI from 
2007 to 2008 for DCIS tumors 5 cm or larger (Figure 3C). There was little variation in 
preoperative breast MRI use by ER status and cancer type within each year (data not 
shown). Use of preoperative breast MRI at hospitals with an NCI sponsored cooperative 
group trial were consistently higher than at hospitals with no such capacity with utilization 
growing at a similar rate (data not shown).
In multivariable analysis for women with DCIS, factors associated with increased odds of 
receiving preoperative breast MRI included younger age, being married, living in a zip code 
with a higher median income, having no comorbidities and being diagnosed in more recent 
years (Table 2). Women with DCIS were more likely to receive preoperative MRI if their 
tumor size was ≥ 2cm (Odds Ratio (OR)=1.30, 95% Confidence Interval (CI): 1.07-1.58 for 
2-4.9cm versus <1cm; OR=1.68, 95%CI: 1.24-2.28 for 5+cm versus <1cm). Additionally, 
having surgery at a hospital that participated in at least one NCI sponsored cooperative 
group trial was associated with increased odds of receiving MRI (OR=1.97, 95%CI: 
1.66-2.33).
Among women with IBC, results of multivariable analysis indicate that preoperative MRI 
use was associated with younger age, white race, being married, living in a zip code with a 
higher median income, having a comorbidity score of zero and having a more recent 
diagnosis. Compared to women with IDC, women with ILC were more likely to receive 
MRI (OR=1.95, 95%CI: 1.90-2.12) as were women with invasive combined lobular/ductal 
disease (OR=1.57, 95%CI: 1.42-1.74). Women with IBC with ER-negative tumors were 
more likely to receive MRI compared to women with ER-positive tumors (OR=1.14, 
95%CI: 1.04-1.24). Similar to the finding observed for women with DCIS, women with IBC 
who received breast surgery at a hospital that participated in at least one NCI sponsored 
cooperative group trial were more likely to receive breast MRI. The main difference 
between the multivariable results for women with DCIS versus those with invasive disease 
was in regard to tumor size; larger DCIS tumor size was associated with receipt of 
preoperative MRI, whereas women with smaller invasive tumors (defined as <1 cm) were 
more likely to receive preoperative MRI.
Our sensitivity analysis adjusting the preoperative window to capture MRIs conducted in the 
30 days prior to the diagnosis date had no notable impact on results (data not shown).
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Discussion
Recent studies across community settings indicate that approximately 15-20% of breast 
MRIs are performed to determine the extent of disease and inform treatment decisions.(16, 
17) Multiple studies have found MRI to be more sensitive than conventional imaging in 
assessing the extent of both DCIS and invasive disease.(18-32) However, the value of MRI 
use in guiding practice is uncertain, in part as studies have not yet demonstrated improved 
outcomes such as fewer re-operations or recurrences when MRI is employed.(8, 33) The 
randomized controlled COMICE Trial that included women scheduled for breast-conserving 
therapy found no significant difference in re-operations rates for the MRI compared to the 
no-MRI group (33), but the trial had methodology limitations including mastectomies 
without pre-operative tissue verification for MRI findings and some low volume facilities 
which may impact generalizability. Further, it has not been definitively shown that MRI 
provides added advantage in particular subgroups of women based on factors such as age, 
breast density or cancer type.
We found that use of MRI for preoperative evaluation of both DCIS and IBC increased 
substantially from 2005 to 2008 and leveled off in 2009. We also observed a 6-fold 
geographic variation during the five-year study period. Correlates of preoperative MRI use 
were similar for women with DCIS and IBC, with the exception of tumor size, which had a 
positive relationship with MRI use in DCIS (larger tumors) but an inverse relationship with 
MRI use in invasive cancers (small tumors). Women with IBC receiving preoperative MRI, 
consistent with previous studies, tended to have tumors that have been shown to be poorly 
visualized on mammography and associated with positive surgical margins, such as lobular 
disease and ER-negative disease. Similarly, we found preoperative breast MRI use was 
associated with large DCIS tumors that are typically associated with greater frequency of 
positive margins.
Our findings are consistent with prior SEER-Medicare studies (3, 5, 34) and add to the 
existing knowledge, specifically for women with ILC, and ER-negative disease. We found 
higher preoperative breast MRI use among women with ILC compared to IDC. ILC is 
challenging to identify with conventional detection methods, likely attributable to its diffuse 
invasive growth pattern. Mammographic false negative rates for ILC have been reported as 
high as 19% (35, 36), and compared to IDC, malignancies that are ILC are more frequently 
larger, bilateral and result in positive surgical margins.(37) In a review of the literature, 
pooled data demonstrated that MRI detected additional otherwise-occult ipsilateral lesions in 
32% of ILC cases and contralateral lesions in 7%.(38) However, a differential benefit of 
MRI in women with ILC compared to those with IDC has not been definitively 
demonstrated. Our results demonstrating more frequent MRI use in ILC likely reflect 
perceived advantages given the limitations of conventional modes of detection.
Several studies have shown that mammography is less sensitive at detecting ER-negative 
compared to ER-positive tumors (39, 40), likely due to the fact that ER-negative cancers 
grow quickly and may be difficult to identify on mammography or lack the typical 
suspicious characteristics of ER positive tumors.(40, 41) In contrast, MRI has been shown to 
better identify ER-negative and triple negative breast cancer.(41) Given that ER-negative 
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tumors have worse prognosis with a higher risk of metastasis and higher risk of local 
recurrence, additional imaging of these tumors with MRI prior to surgical treatment may be 
warranted.(42, 43)
We also found for women with DCIS or IBC, hospital participation in NCI cooperative 
group trials is associated with receipt of preoperative breast MRI. The fact that women seen 
at a hospital that participated in an NCI-sponsored cooperative group trial were 
approximately two times more likely to receive preoperative breast MRI suggests that 
despite a lack of clear evidence of improved outcomes from using preoperative breast MRI, 
this emerging technology is being utilized differentially and more frequently among 
academic or research-focused practices, perhaps due to the NCCN guidelines.
There are several limitations of using SEER-Medicare data. Due to the nature of SEER data, 
several tumor variables (size, stage) may be those from final surgery, and not reflect the 
preoperative tumor characteristics. Since the SEER program collects tumor characteristics 
based on all available evidence within the initial treatment window, some information such 
as pathologic findings may differ substantially from preoperative estimates. In addition, we 
are unable to assess the use of neoadjuvant chemotherapy because of the challenges of doing 
so with claims data.
Overall, we found that the frequency with which preoperative breast MRI is performed is 
similar for women diagnosed with DCIS and IBC. Among women with IBC, those with ILC 
and those with ER-negative tumors were more likely to receive preoperative breast MRI 
suggesting that MRI is being performed more commonly among women diagnosed with 
invasive tumors that may not be well visualized on mammography. For women with DCIS, 
MRI was associated with larger lesions, which may be associated with greater frequency of 
positive margins. To better understand the use of this imaging tool, future studies should 
examine additional patient factors such as family history of breast cancer and breast density, 
tumor subtypes, and physician and hospital characteristics of women receiving preoperative 
MRI and also include a population of younger women.
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Figure 1. 
Proportion of women with non-metastatic breast cancer receiving preoperative breast MRI 
by year and cancer type, SEER-Medicare 2005-2009
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Figure 2. 
Proportion of women with non-metastatic breast cancer receiving preoperative breast MRI 
by SEER location and cancer type, SEER-Medicare 2005-2009
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Figure 3. 
Proportion of women with non-metastatic breast cancer receiving preoperative breast MRI 
by year, cancer type, and patient/tumor characteristics: A, race; B, histology; C, tumor size.
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Table 1
Characteristics of the cohort by preoperative breast magnetic resonance imaging (MRI) use and cancer type 
(Ductal Carcinoma In-Situ (DCIS) versus Invasive Breast Cancer (IBC)), SEER-Medicare, 2005-2009
DCIS IBC
No MRI N=7,595 
(84.7%)
MRI N=1,372 (15.3%) No MRI N=38,770 
(83.7%)
MRI N=7,607 (16.3%)
Characteristic N %a N %a N %a N %a
Age Group, years
    66-69 1679 22.1 436 31.8 7072 18.2 2232 29.3
    70-74 2083 27.4 451 32.9 9266 23.9 2381 31.3
    75-79 1939 25.5 309 22.5 9114 23.5 1670 22.0
    80-84 1245 16.4 138 10.1 7624 19.7 939 12.3
    85+ 649 8.6 38 2.8 5694 14.7 385 5.1
Race
    White 6433 84.7 1209 88.1 33858 87.3 6936 91.2
    Black 689 9.1 79 5.8 2938 7.6 321 4.2
    Other 473 6.2 84 6.1 1974 5.1 350 4.6
Residenceb
    Urban 6900 90.9 1313 95.7 34486 89.0 7189 94.5
    Rural 695 9.2 59 4.3 4284 11.1 418 5.5
Marital status
    Not married 3725 49.1 510 37.2 20937 54.0 3248 42.7
    Married 3498 46.1 806 58.8 16401 42.3 4056 53.3
    Unknown 372 4.9 56 4.1 1432 3.7 303 4.0
Median Income of Zip Code
    < $35,801 1923 25.3 180 13.1 10591 27.3 1130 14.9
    $35,801 - 47,300 1858 24.5 292 21.3 10126 26.1 1675 22.0
    $47,301 - 64,200 1900 25.0 381 27.8 9608 24.8 2074 27.3
    > $64,200 1914 25.2 519 37.8 8445 21.8 2728 35.9
Comorbidity indexc
    0 4671 61.5 979 71.4 23514 60.7 5458 71.8
    1 1941 25.6 283 20.6 9569 24.7 1526 20.1
    2+ 983 12.9 110 8.0 5687 14.7 623 8.2
Histology
    DCIS 7595 100.0 1372 100.0
    Invasive Ductal 28935 74.6 5206 68.4
    Invasive Lobular 3881 10.0 1221 16.1
    Invasive Ductal and Lobular 2490 6.4 726 9.5
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DCIS IBC
No MRI N=7,595 
(84.7%)
MRI N=1,372 (15.3%) No MRI N=38,770 
(83.7%)
MRI N=7,607 (16.3%)
Characteristic N %a N %a N %a N %a
    Invasive, Other 3464 8.9 454 6.0
Grade
    High 935 12.3 140 10.2 9331 24.1 1943 25.5
    Intermediate 2451 32.3 455 33.2 16851 43.5 3563 46.8
    Low 2876 37.9 580 42.3 10597 27.3 1781 23.4
    Unknown 1333 17.6 197 14.4 1991 5.1 320 4.2
Stage
    0 7595 100.0 1372 100.0
    I 21650 55.8 4421 58.1
    II 13097 33.8 2541 33.4
    III 4023 10.4 645 8.5
Tumor Size
    <1cm 2101 27.7 393 28.6 8426 21.7 1782 23.4
    1 to <2 cm 1486 19.6 294 21.4 14721 38.0 3154 41.5
    2 to <5cm 1090 14.4 265 19.3 12722 32.8 2214 29.1
    5+ cm 266 3.5 78 5.7 2329 6.0 361 4.8
    Unknown 2652 34.9 342 24.9 572 1.5 96 1.3
Estrogen Receptor Status
    Positive 4480 59.0 883 64.4 30703 79.2 6305 82.9
    Negative 1154 15.2 242 17.6 5869 15.1 1053 13.8
    Unknown 1961 25.8 247 18.0 2198 5.7 249 3.3
Teaching Hospitald
    No 2520 33.2 442 32.2 15401 39.7 2573 33.8
    Yes 2829 37.3 549 40.0 15220 39.3 3425 45.0
    Unknown 2246 29.6 381 27.8 8149 21.0 1609 21.2
Membership in an NCI 
Cooperative Group Triale
    No 2477 32.6 292 21.3 15312 39.5 1912 25.1
    Yes 2902 38.2 705 51.4 15464 39.9 4129 54.3
    Unknown 2216 29.2 375 27.3 7994 20.6 1566 20.6
a
The percent shown is the column percent.
b
Residence is based on the woman's county of residence at time of breast cancer diagnosis and is categorized into urban which includes big 
metropolitan, metropolitan, and urban versus rural which includes less urban and rural counties.
cComorbidity Index is based on the method of Klabunde et al.(14)
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d
Teaching hospital is based on the hospital where the breast surgery was performed.
e
Membership in an NCI Cooperative group trial indicates if the hospital where the surgery was performed participated in at least one NCI trial.
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Table 2
Multivariable logistic regression models for association between receipt of MRI and patient, tumor, and 
hospital characteristics, SEER-Medicare 2005-2009
Ductal Carcinoma In-Situ Invasive Breast Cancer
Characteristic Category OR (95% CI)a p-value OR (95% CI)a p-value
Age Group, years 66-69 Referent <0.0001 Referent <0.0001
70-74 0.88 (0.75, 1.03) 0.80 (0.74, 0.86)
75-79 0.67 (0.56, 0.80) 0.60 (0.55, 0.65)
80-84 0.44 (0.36, 0.56) 0.39 (0.36, 0.43)
85+ 0.23 (0.16, 0.33) 0.20 (0.18, 0.23)
Race White Referent 0.84 Referent <0.0001
Black 0.92 (0.69, 1.21) 0.77 (0.67, 0.88)
Other 0.89 (0.68, 1.18) 0.79 (0.69, 0.90)
SEER Registry California Referent <0.0001 Referent <0.0001
Utah 0.52 (0.31, 0.87) 0.65 (0.54, 0.79)
Seattle 1.37 (1.06, 1.77) 1.72 (1.54, 1.91)
San Jose 0.45 (0.29, 0.71) 0.51 (0.42, 0.62)
San Francisco 0.32 (0.21, 0.47) 0.44 (0.37, 0.53)
Rural Georgia 0.41 (0.05, 3.43) 0.43 (0.19, 0.95)
New Mexico 1.58 (0.98, 2.55) 2.09 (1.74, 2.51)
New Jersey 0.70 (0.57, 0.87) 0.69 (0.63, 0.76)
Louisiana 0.53 (0.38, 0.74) 0.53 (0.45, 0.61)
Los Angeles 1.20 (0.93, 1.55) 1.54 (1.38, 1.71)
Kentucky 0.18 (0.12, 0.29) 0.28 (0.23, 0.33)
Iowa 0.35 (0.23, 0.52) 0.42 (0.35, 0.49)
Hawaii 0.10 (0.04, 0.29) 0.08 (0.04, 0.15)
Greater Georgia 0.38 (0.28, 0.51) 0.40 (0.35, 0.46)
Detroit 0.31 (0.22, 0.45) 0.53 (0.46, 0.62)
Connecticut 0.68 (0.52, 0.89) 0.75 (0.66, 0.84)
Atlanta 0.84 (0.60, 1.17) 0.64 (0.54, 0.76)
Residenceb Urban Referent 0.49 Referent 0.87
Rural 1.12 (0.80, 1.57) 1.01 (0.89, 1.15)
Married Married Referent <0.0001 Referent <0.0001
Not married 0.75 (0.65, 0.86) 0.87 (0.82, 0.92)
Median Income <= $35,800 Referent <0.0001 Referent <0.0001
$35,801-$47,300 1.42 (1.14, 1.76) 1.32 (1.21, 1.45)
$47,301-$64,200 1.62 (1.3, 2.02) 1.58 (1.44, 1.73)
>$64,200 2.02 (1.62, 2.52) 2.21 (2.01, 2.43)
Comorbidity Scorec None Referent <0.0001 Referent <0.0001
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Ductal Carcinoma In-Situ Invasive Breast Cancer
Characteristic Category OR (95% CI)a p-value OR (95% CI)a p-value
1 0.77 (0.66, 0.90) 0.78 (0.73, 0.84)
2+ 0.60 (0.47, 0.75) 0.57 (0.51, 0.62)
Diagnosis Year 2005 Referent <0.0001 Referent <0.0001
2006 1.57 (1.20, 2.06) 1.67 (1.50, 1.86)
2007 2.98 (2.31, 3.85) 3.05 (2.75, 3.39)
2008 5.41 (4.25, 6.90) 4.42 (4.00, 4.89)
2009 4.94 (3.87, 6.31) 4.94 (4.47, 5.46)
Histology Invasive Ductal Referent <0.0001
Invasive Lobular 1.95 (1.80, 2.12)
Invasive Lobular & Ductal 1.57 (1.42, 1.74)
Invasive Other n/a 0.87 (0.78, 0.98)
Grade Low Referent 0.56 Referent 0.01
Intermediate 0.91 (0.78, 1.07) 1.10 (1.02, 1.19)
High 0.96 (0.77, 1.20) 1.09 (1.00, 1.10)
Unknown 0.89 (0.73, 1.09) 0.93 (0.80, 1.08)
Stage I Referent 0.01
II n/a 1.18 (1.09, 1.28)
III 1.07 (0.94, 1.21)
Tumor Size <1cm Referent <0.0001 Referent 0.0003
1 to <2cm 1.09 (0.91, 1.31) 1.04 (0.97, 1.12)
2cm to <5cm 1.30 (1.07, 1.58) 0.83 (0.75, 0.92)
5+ cm 1.68 (1.24, 2.28) 0.76 (0.65, 0.90)
Unknown 0.82 (0.68, 0.97) 0.95 (0.74, 1.22)
Estrogen Receptor Positive Referent 0.05 Referent 0.001
Negative 1.13 (0.94, 1.35) 1.14 (1.04, 1.24)
Unknown 0.84 (0.70, 0.99) 0.81 (0.69, 0.94)
Teaching Hospitald No Referent 0.58 Referent 0.01
Yes 0.95 (0.81, 1.12) 1.09 (1.02, 1.17)
Unknown 0.63 (0.23, 1.72) 1.44 (0.98, 2.11)
Member of NCI Cooperative Group 
Triale
No Referent <0.0001 Referent <0.0001
Yes 1.97 (1.66, 2.33) 1.94 (1.81, 2.07)
Unknown 2.08 (0.75, 5.78) 0.97 (0.66, 1.43)
aOR = odds ratio; 95%CI = 95% confidence interval.
b
Residence is based on the woman's county of residence at time of breast cancer diagnosis and is categorized into urban which includes big 
metropolitan, metropolitan, and urban versus rural which includes less urban and rural counties.
cComorbidity Index is based on the method of Klabunde et al.(14)
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d
Teaching hospital is based on the hospital where the breast surgery was performed.
e
Membership in an NCI Cooperative group trial indicates if the hospital where the surgery was performed participated in at least one NCI trial.
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